ZyVersa Therapeutics Overview
Valuation check: ZVSA's ROE is 173.38%, above the sector sector average of -6.13%.
Get informed when a big investor buys or sells
+ Follow173.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, ZVSA shows a ROE of 173.38%. That is above the sector sector average of -6.13%. Scroll down for historical charts and peer comparison views.
The its sector sector average ROE is about -6.13%. ZyVersa Therapeutics is at 173.38%, which is higher that average. That is roughly 2929.2% above the sector mean. Use the comparison chart on this page to see how ZVSA stacks up against individual peers as well.
Check the historical chart to see whether ZVSA's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare ZyVersa Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has ZyVersa Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 173.38%) with ownership activity and broader fundamentals.
